Lifitegrast
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Lifitegrast?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Lifitegrast, sold under the brand name Xiidra (/ˈzaɪdrə/[2]), is a medication for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca. Lifitegrast reduces inflammation by inhibiting inflammatory cell binding.[3] It is often used in conjunction with ciclosporin (Ikervis, Restasis, or Cequa) for dry eye treatment including meibomian gland dysfunction and inflammatory dry eye.
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Xiidra |
Other names | SAR-1118 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a616039 |
Pregnancy category |
|
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.245.695 |
Chemical and physical data | |
Formula | C29H24Cl2N2O7S |
Molar mass | 615.48 g·mol−1 |
3D model (JSmol) | |
| |
|
Close